Peripheral plasma immunoreactive 6-oxo-prostaglandin F1 alpha and gynaecological tumours.
Peripheral plasma levels of immunoreactive 6-oxo-PGF1 alpha, the stable hydrolysis product of prostacyclin, were significantly higher in female patients with tumours of the genital tract than in normal controls. In the groups with malignant tumours, these high levels declined after operation and/or radiotherapy if the tumour responded to treatment. In patients who did not respond to treatment or with tumour recurrence, levels of plasma 6-oxo-PGF1 alpha remained high or even rose further. Benign gynaecological tumours were also associated with significantly raised plasma 6-oxo-PGF1 alpha levels, and these fell to normal levels immediately on surgical removal of the tumour. Possible reasons for these alterations are described. Further investigations are warranted to see whether serial measurements of plasma 6-oxo-PGF1 alpha could be used as a prognostic index for the clinical status of patients with gynaecological tumours.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood*; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005833:Genital Neoplasms, Female / Q000378:metabolism* / Q000532:radiotherapy / Q000628:therapy; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D011379:Prognosis; D011460:Prostaglandins F / Q000097:blood*
D000970:Antineoplastic Agents; D011460:Prostaglandins F; D015121:6-Ketoprostaglandin F1 alpha; C100006:prostaglandin F1